# A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.

> **NCT07340424** · EARLY_PHASE1 · RECRUITING · sponsor: **Xiaorong Sun** · enrollment: 15 (estimated)

## Conditions studied

- Advanced Metastatic Triple-negative Breast Cancer (mTNBC)

## Interventions

- **DRUG:** 225Ac-TR2205 Injection

## Key facts

- **NCT ID:** NCT07340424
- **Lead sponsor:** Xiaorong Sun
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-22
- **Primary completion:** 2027-04
- **Final completion:** 2029-05
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07340424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07340424, "A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07340424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*